Selected article for: "acute respiratory syndrome and effective concentration"
Author: Gendrot, Mathieu; Jardot, Priscilla; Delandre, Océane; Boxberger, Manon; Andreani, Julien; Duflot, Isabelle; Le Bideau, Marion; Mosnier, Joel; Fonta, Isabelle; Hutter, Sébastien; La Scola, Bernard; Pradines, Bruno
Title: In Vitro Evaluation of the Antiviral Activity of Methylene Blue Alone or in Combination against SARS-CoV-2
  • Cord-id: 88hnzxer
  • Document date: 2021_7_6
    • ID: 88hnzxer
    Snippet: A new severe acute respiratory syndrome coronavirus (SARS-CoV-2) causing coronavirus diseases 2019 (COVID-19), which emerged in Wuhan, China in December 2019, has spread worldwide. Currently, very few treatments are officially recommended against SARS-CoV-2. Identifying effective, low-cost antiviral drugs with limited side effects that are affordable immediately is urgently needed. Methylene blue, a synthesized thiazine dye, may be a potential antiviral drug. Antiviral activity of methylene blue
    Document: A new severe acute respiratory syndrome coronavirus (SARS-CoV-2) causing coronavirus diseases 2019 (COVID-19), which emerged in Wuhan, China in December 2019, has spread worldwide. Currently, very few treatments are officially recommended against SARS-CoV-2. Identifying effective, low-cost antiviral drugs with limited side effects that are affordable immediately is urgently needed. Methylene blue, a synthesized thiazine dye, may be a potential antiviral drug. Antiviral activity of methylene blue used alone or in combination with several antimalarial drugs or remdesivir was assessed against infected Vero E6 cells infected with two clinically isolated SARS-CoV-2 strains (IHUMI-3 and IHUMI-6). Effects both on viral entry in the cell and on post-entry were also investigated. After 48 h post-infection, the viral replication was estimated by RT-PCR. The median effective concentration (EC(50)) and 90% effective concentration (EC(90)) of methylene blue against IHUMI-3 were 0.41 ± 0.34 µM and 1.85 ± 1.41 µM, respectively; 1.06 ± 0.46 µM and 5.68 ± 1.83 µM against IHUMI-6. Methylene blue interacted at both entry and post-entry stages of SARS-CoV-2 infection in Vero E6 cells as retrieved for hydroxychloroquine. The effects of methylene blue were additive with those of quinine, mefloquine and pyronaridine. The combinations of methylene blue with chloroquine, hydroxychloroquine, desethylamodiaquine, piperaquine, lumefantrine, ferroquine, dihydroartemisinin and remdesivir were antagonist. These results support the potential interest of methylene blue to treat COVID-19.

    Search related documents:
    Co phrase search for related documents
    • abdominal pain and lung damage: 1
    • abdominal pain and lung inflammatory: 1
    • abdominal pain and lung tissue: 1, 2
    • abdominal pain and maculopapular rash: 1, 2, 3, 4, 5
    • acute sars respiratory syndrome coronavirus and low cost approach: 1, 2, 3, 4, 5, 6, 7
    • acute sars respiratory syndrome coronavirus and low micromolar: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • acute sars respiratory syndrome coronavirus and low micromolar range: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute sars respiratory syndrome coronavirus and lung accumulate: 1, 2
    • acute sars respiratory syndrome coronavirus and lung blood: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars respiratory syndrome coronavirus and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars respiratory syndrome coronavirus and lung inflammatory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars respiratory syndrome coronavirus and lung inflammatory response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • acute sars respiratory syndrome coronavirus and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars respiratory syndrome coronavirus and maculopapular rash: 1, 2, 3, 4, 5, 6, 7
    • low cost approach and lung damage: 1, 2
    • low cost approach and lung inflammatory: 1, 2